VA-AFTON-CHEMICAL
Afton Chemical is excited to introduce Microbotz™, heroes of protection and performance for our Industrial lubricant additive Portfolio.
The world of Industrial lubricants is complex with a multitude of products serving an ever-growing and diverse range of end-use industries, with frequent overlap between products and applications.
Afton Chemical’s new global marketing campaign seeks to make life easier for Industrial lubricant marketers with an applications-based approach. A unique family of seven heroic micro-robot characters, known as the Microbotz™, have been created to represent each of the seven application groups within the Afton’s Industrial Additives Portfolio: Wind Turbine; Industrial Gear; Turbine; Hydraulic; Grease; Slideway; and Metalworking.
Each is a champion of their application area and an expert in the world of Industrial lubricants. Their role is to guide our customers and industry partners through the Afton Industrial range, promoting new solutions, advising them about the benefits of Afton’s technology to their business, informing them about the industrial market and helping them to stay at the forefront of their industry sectors.
Sarah Flower, Senior Marketing Manager at Afton Chemical commented: “The Industrial lubricant landscape can sometimes be challenging to navigate, and we found there was a need for an innovative and engaging marketing approach to bring it to life. Individually, each of our Microbotz™ characters will explain Industrial Additives in the context of real world end-use applications. As their story unfolds we journey with them as they patrol the lubricant, deep inside the chemistry, protecting each application from a variety of potential enemies – be that oxidation and sludge formation, contaminants, wear, rust or heat. The aim is to demonstrate how our additives work to prolong the life of the lubricants they serve and improve the performance of industrial machinery.”
As part of this new campaign, customers will have access to a limited edition collectible box set of Guides to Industrial Lubricants. Seven books will be published. Each book will include chapters on end-use applications, lubrication needs, key OEMs, significant tests and specifications, market trends as well as the corresponding Afton Industrial product range. The first book in the series focuses on Turbine applications, and is due out later this summer.
For more information or to sign up to receive the limited edition box set of Guides to Industrial Lubricants, visit Afton’s new Microbotz™ site at: www.aftonmicrobotz.com
About Afton Chemical
Afton Chemical Corporation, is part of the NewMarket Corporation (NYSE: NEU) family of companies. Afton uses our formulation, engineering and marketing expertise to help our customers develop and market fuels and lubricants that reduce emissions, improve fuel economy, extend equipment life, improve operator and driver satisfaction and lower the total cost of vehicle and equipment operation. We are leaders in fuel economy improvement, emission reduction and wear control technology. We offer performance fuel additives and refinery chemicals, such as gasoline and diesel performance additives, lubricity improvers, and cold flow improvers; driveline additives, such as automotive gear oil and automatic transmission fluid additives; engine oil additives for passenger car, heavy duty diesel and railroad and marine diesel engines; additives for industrial products, such as wind turbine lubricants, industrial gear oils, turbine oils, hydraulic oils, grease, slideway oils, metalworking fluids and industrial specialty chemicals. The company supports global operations through regional headquarters located in Asia Pacific, EMEAI, Latin America and North America. Afton Chemical Corporation is headquartered in Richmond, Virginia.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130612005034/en/
Contact:
Afton Chemical Corporation
Sarah Flower, Senior Marketing Manager –
Industrial, EMEAI
+44 1344 356520 (UK)
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum